Articles

  • 2 days ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

    Author(s):,Panelists discuss how recent trials, including KEYNOTE-057, QUILT-3.032, and CORE-001, highlight the promising efficacy, durability, and manageable safety profiles of novel treatments like pembrolizumab, nogapendekin alfa inbakicept, and nadofaragene firadenovec, while also exploring the potential of combination therapies and novel intravesical options like TAR-200 and UGN-102 for improving outcomes in non–muscle-invasive bladder cancer (NMIBC).

  • 2 days ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

    Author(s):,Panelists discuss how the ongoing ABLE-32 and ABLE-41 trials are exploring the efficacy and safety of nadofaragene firadenovec in different NMIBC patient populations, with ABLE-32 focusing on intermediate-risk patients and ABLE-41 examining real-world effectiveness and safety. The ongoing clinical trials investigating nadofaragene firadenovec include the ABLE-32 and ABLE-41 trials, each focusing on different aspects of its use in treating non-muscle invasive bladder cancer (NMIBC).

  • 1 week ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

    Author(s):,Panelists discuss how real-world data from a recent Mayo Clinic study confirms the promising efficacy and favorable safety profile of nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting high cystectomy-free and overall survival rates, with longer follow-up needed to assess response durability.

  • 1 week ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

    Author(s):,Panelists discuss how nogapendekin alfa, an intravesical immunotherapy that stimulates a localized immune response, combined with BCG therapy, provides a novel dual approach for treating BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), targeting both local and systemic immune responses.

  • 2 weeks ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

    Author(s):,Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
44
Tweets
0
DMs Open
No
No Tweets found.